Data Capture to Measure, Track, and Improve Antibiotic Use

Duke-Margolis Center for Health Policy

Webinar Agenda | March 2, 2023 | 1:00 – 2:35 pm ET

About the Webinar

Policymakers, policy researchers, and stakeholders combating drug-resistant infections are invited to join Duke-Margolis and learn about capturing data to track and measure antibiotic use and antibiotic resistance. Viewers will learn why doing so is important for clinical care, antibiotic stewardship, and antibiotic development.

Dr. Mark McClellan will moderate two panel discussions during which panelists will discuss how to identify and answer clinical questions with antibiotic use data, as well as policy approaches to improve data capture for antibiotic use. Discussion will inform policy approaches that post-market incentives for novel antibiotics might include to improve how data is captured to measure, track, and improve antibiotic use and patient outcomes.

1:00 pm	**Welcome and Opening Remarks**
	Mark McClellan, Director, Duke-Margolis Center for Health Policy
1:05 pm	**Session 1: Answering Clinical Questions with Antibiotic Use Data**
	Moderator: Mark McClellan
	Effective antibiotics are critical to modern medical care and enable clinicians to treat a range of bacterial infections. Unfortunately, the development and spread of antibiotic resistance and drug-resistant infections poses a severe and growing threat to us all.
	To counter drug-resistant infections, clinicians and infectious disease specialists rely on their experience with antibiotics and clinical evidence from studies of antibiotic efficacy and real-world use. However, answering questions about novel antibiotics, their efficacy and effectiveness, and their impact on patient outcomes can be particularly challenging and labor intensive.
	During this session, panelists will discuss what clinicians want to know about novel antibiotics that can be used to treat drug-resistant infections and how clinical data regarding antibiotic use and patient outcomes is captured. Panelists will also discuss industry's role in conducting studies of novel antibiotics and what challenges a

variety of stakeholders encounter developing clinical evidence about novel antibiotics.

Panel Discussion

- **Libby Dodds Ashley**, Duke University
- **Shira Doron**, Tufts Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance
- **Simon Portsmouth**, Shionogi Inc.

1:45 pm   **Session 2: Policy Approaches to Improve Data Capture for Antibiotic Use**

Moderator: Mark McClellan

Hospitals, federal agencies like the CDC, and antibiotic developers all capture data to measure and track antibiotic use and antibiotic resistance (AR). And despite the shift toward electronic medical records, data that is systematically captured for AR surveillance or antibiotic stewardship can be limited and siloed, complicating clinical studies and guidance development.

During this session, panelists will discuss why changes to expand data capture might be necessary to enable clinical studies and advance clinical evidence about novel antibiotics, including patient outcomes studies. Panelists will also discuss barriers that various stakeholders encounter, and whether pull incentives for novel antibiotics can support data capture that advances both AR surveillance and clinical evidence for novel antibiotics.

Panel Discussion

- **Tamar F. Barlam**, Boston Medical Center
- **Rebecca Li**, Vivli Inc.
- **David Hyun**, The Pew Charitable Trusts
- **Arjun Srinivasan**, U.S. Centers for Disease Control and Prevention

2:30 pm   **Closing Remarks**

Mark McClellan

2:35 pm   **Adjournment**